Legalon capsules 140mg №10×3

Name:
Legalon.
Description:
The appearance of the capsule is brown hard gelatin capsules, size “1”. The appearance of the contents of the capsule is a yellow powder. The main active ingredient is Silymarin. Release formCapsules. Dosage 140 mg. Special indicationsPharmacotherapeutic group Means for the treatment of liver diseases, lipotropic agents. ATX code: A05BA03. Pharmacological action The antitoxic action of silymarin has been demonstrated in animal studies using numerous models of liver damage, for example, poisons of the pale toadstool (phalloidin and amanitin), as well as lanthanides, carbon tetrachloride, galactosamine, thiocetamine and hepatotoxic frog virus FV3. The therapeutic effect of silymarin is associated with several mechanisms of action: due to the ability to bind free radicals, silymarin has antioxidant activity, stopping or preventing the pathophysiological process of lipid peroxidation, which leads to the destruction of cell membranes. In addition, in already damaged liver cells, silymarin stimulates protein synthesis and normalizes the metabolism of phospholipids. The general result of its action is the stabilization of the cell membrane, as well as the weakening or prevention of the loss of intracellular contents in dissolved form (for example, transaminases). Silymarin limits the entry into the cell of certain hepatotoxic substances (poisons of the pale toadstool). Silymarin activates protein synthesis by stimulating RNA polymerase I, an enzyme localized in the nucleus. This leads to increased formation of ribosomal RNA, due to which structural and functional proteins (enzymes) are synthesized in greater quantities. As a result, the reparative capacity and regenerative potential of the liver increase. Pharmacokinetics Indications for use Liver toxicity: for maintenance therapy in patients with chronic inflammatory liver disease or cirrhosis. Note: Treatment with Legalon® 140 is effective only if the effect of a toxic agent that causes liver damage (eg alcohol) is eliminated. This medicinal product is not suitable for treatment in case of acute poisoning. Dosage and Administration Unless otherwise indicated, adults and children over 12 years of age are recommended to take 1 capsule 3 times a day, which corresponds to 324.6 mg of silymarin (HPLC) or 420 silymarin (DNPH). Capsules should be swallowed whole, without chewing, drink plenty of liquid. There are no data available regarding use in patients with renal insufficiency. Use in children under 12 years of age: This medicinal product is not intended for use in children under 12 years of age. Method of application and duration: For oral use; The capsules should be swallowed whole, without chewing, with a sufficient amount of liquid. The duration of the course of treatment is determined by the doctor individually, depending on the nature and characteristics of the course of the disease. Use during pregnancy and lactation There is no information about the experience of using this drug in pregnant women. Animal studies are insufficient in relation to the study of reproductive toxicity. Therefore, the use of the drug during pregnancy is not recommended. It is not known whether the active components of the drug and their metabolites are excreted in human breast milk. A risk to neonates/infants cannot be excluded. Therefore, the use of the drug during breastfeeding is not recommended. Research data on the effect of active components on fertility are insufficient. Influence on the ability to drive vehicles and other mechanisms The drug does not affect the ability to drive motor vehicles and maintain moving mechanical devices. PrecautionsTreatment with this drug is not a substitute for not taking a substance that causes liver damage (such as alcohol). If signs of jaundice appear (acquisition of a skin tone from light yellow to dark yellow, yellowing of the whites of the eyes), it is necessary to consult a doctor. Use of the drug in children: There are insufficient data on the efficacy and safety of the drug in children. The drug is not recommended for use in children under 12 years of age. Interaction with other drugs Not known. Contraindications Legalon® 140 is contraindicated in persons with known hypersensitivity to milk thistle fruits, other drug components or excipients. Composition 1 capsule contains: Active substance: milk thistle fruit dry extract (36-44:1) – 173.0-186.7 mg, equivalent to 140 mg of silymarin (DNPH), equivalent to 108.2 mg of silymarin (HPLC / DE.P. ) in terms of silibinin. Excipients: polysorbate 80, povidone, mannitol, sodium carboxymethyl starch (type A), magnesium stearate. Shell: hard gelatin capsule, size “1”, which includes: gelatin, iron dye red oxide (E172), titanium dioxide (E171), sodium lauryl sulfate, iron dye black oxide (E172). Overdose Signs or symptoms of overdose or poisoning have not yet been registered. The undesirable effects described above may be exacerbated. No specific antidote is known. If necessary, symptomatic measures are recommended. Side effect Criteria for assessing the frequency of development of an adverse drug reaction: very often (≥1/10), often (≥1/100, <1/10), infrequently (≥1/1000, <1/100), rarely (≥1/10 10,000, <1/1000), very rare (<1/10,000), unknown - the frequency cannot be determined based on the available data. In rare cases, the following side effects can be observed: Gastrointestinal disorders: rarely - mild diarrhea; Immune system disorders: very rarely - hypersensitivity reactions are possible; Respiratory, thoracic and mediastinal disorders: very rare - dyspnea; Skin and subcutaneous tissue disorders: very rarely - itching. All cases of unusual reactions associated with the use of the drug must be reported by e-mail to the representative of the applicant ([email protected]). Storage conditions Store in a place protected from light, at a temperature not exceeding 30 °C. Keep out of the reach of children. Buy Legalon capsules 140mg №10x3 Price for Legalon capsules 140mg №10x3Instruction for use for Legalon capsules 140mg №10x3